Evidence map›Paper›PMID 36144005›Full record

ArticleMicromachines2022

Production of Inhalable Ultra-Small Particles for Delivery of Anti-Inflammation Medicine via a Table-Top Microdevice.

Matthew J Owen, Umit Celik, Subash K Chaudhary, Jasper H N Yik, John S Patton, Mei-Chang Kuo, Dominik R Haudenschild, Gang-Yu Liu

Open access · goldAbstract read
In one paragraph

Article in Micromachines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Matthew J OwenDepartment of Chemistry, University of California, Davis, CA 95616, USA.ORCID 0000-0001-7119-8374
Umit CelikDepartment of Chemistry, University of California, Davis, CA 95616, USA.ORCID 0000-0002-7759-6821
Subash K ChaudharyDepartment of Chemistry, University of California, Davis, CA 95616, USA.
Jasper H N YikTesio Pharmaceuticals, Inc., Davis, CA 95616, USA.
John S PattonTesio Pharmaceuticals, Inc., Davis, CA 95616, USA.
Mei-Chang KuoTesio Pharmaceuticals, Inc., Davis, CA 95616, USA.
Dominik R HaudenschildDepartment of Orthopedic Surgery, School of Medicine, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0001-9947-9864
Gang-Yu LiuDepartment of Chemistry, University of California, Davis, CA 95616, USA.
University of California, Davis · US

Funding

United States Department of Defense CDMRP, PR171305
6 · The paper itself

Abstract

A table-top microdevice was introduced in this work to produce ultrasmall particles for drug delivery via inhalation. The design and operation are similar to that of spray-drying equipment used in industry, but the device itself is much smaller and more portable in size, simpler to operate and more economical. More importantly, the device enables more accurate control over particle size. Using Flavopiridol, an anti-inflammation medication, formulations have been developed to produce inhalable particles for pulmonary delivery. A solution containing the desired components forms droplets by passing through an array of micro-apertures that vibrate via a piezo-electrical driver. High-purity nitrogen gas was introduced and flew through the designed path, which included the funnel collection and cyclone chamber, and finally was pumped away. The gas carried and dried the micronized liquid droplets along the pathway, leading to the precipitation of dry solid microparticles. The formation of the cyclone was essential to assure the sufficient travel path length of the liquid droplets to allow drying. Synthesis parameters were optimized to produce microparticles, whose morphology, size, physio-chemical properties, and release profiles met the criteria for inhalation. Bioactivity assays have revealed a high degree of anti-inflammation. The above-mentioned approach enabled the production of inhalable particles in research laboratories in general, using the simple table-top microdevice. The microparticles enable the inhalable delivery of anti-inflammation medicine to the lungs, thus providing treatment for diseases such as pulmonary fibrosis and COVID-19.

Indexed as

COVIDdrug releaseFlavopiridolinflammationinhalable particlespulmonary delivery

Identifiers

PMID36144005
PMCPMC9501338
OpenAlexW4293221051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.